Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty
Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho